CoChat
Sign Up
Cited by 4CRISPR and Genetic EngineeringBacterial Genetics and BiotechnologyRNA regulation and disease

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

RNA processing by the CRISPR-associated NYN ribonuclease

Open access
Chi, Haotian, White, Malcolm F.·2024·Biochemical Journal
DOI 10.1042/bcj20240151PMC PMC11346440

Published version of a preprint

Open this paper in CoChat — free accountOpen PDF

Abstract

CRISPR-Cas systems confer adaptive immunity in prokaryotes, facilitating the recognition and destruction of invasive nucleic acids. Type III CRISPR systems comprise large, multisubunit ribonucleoprotein complexes with a catalytic Cas10 subunit. When activated by the detection of foreign RNA, Cas10 generates nucleotide signalling molecules that elicit an immune response by activating ancillary effector proteins. Among these systems, the Bacteroides fragilis type III CRISPR system was recently shown to produce a novel signal molecule, SAM-AMP, by conjugating ATP and SAM. SAM-AMP regulates a membrane effector of the CorA family to provide immunity. Here, we focus on NYN, a ribonuclease encoded within this system, probing its potential involvement in crRNA maturation. Structural modelling and in vitro ribonuclease assays reveal that NYN displays robust sequence-nonspecific, Mn2+-dependent ssRNA-cleavage activity. Our findings suggest a role for NYN in trimming crRNA intermediates into mature crRNAs, which is necessary for type III CRISPR antiviral defence. This study sheds light on the functional relevance of CRISPR-associated NYN proteins and highlights the complexity of CRISPR-mediated defence strategies in bacteria.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1042/bcj20240151

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 48

  1. 2014, Molecular mechanisms of CRISPR-mediated microbial immunity, Cell. Mol. Life Sci., 71, 449, 10.1007/s00018-013-1438-6 · DOI
  2. 2018, The biology of CRISPR-Cas: backward and forward, Cell, 172, 1239, 10.1016/j.cell.2017.11.032 · DOI
  3. 2020, CRISPR adaptation from a structural perspective, Curr. Opin. Struct. Biol., 65, 17, 10.1016/j.sbi.2020.05.015 · DOI
  4. 2015, CRISPR adaptation biases explain preference for acquisition of foreign DNA, Nature, 520, 505, 10.1038/nature14302 · DOI
  5. Barrangou, 2013, CRISPR-Cas Systems, 115, 10.1007/978-3-642-34657-6 · DOI
  6. 2020, Molecular mechanisms of CRISPR-Cas immunity in bacteria, Annu. Rev. Genet., 54, 93, 10.1146/annurev-genet-022120-112523 · DOI
  7. 2020, Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants, Nat. Rev. Microbiol., 18, 67, 10.1038/s41579-019-0299-x · DOI · Paper page
  8. 2017, Diversity, classification and evolution of CRISPR-Cas systems, Curr. Opin. Microbiol., 37, 67, 10.1016/j.mib.2017.05.008 · DOI · Paper page
  9. 2015, An updated evolutionary classification of CRISPR–Cas systems, Nat. Rev. Microbiol., 13, 722, 10.1038/nrmicro3569 · DOI · Paper page
  10. 2021, Cyclic oligoadenylate signalling and regulation by ring nucleases during type III CRISPR defence, RNA, 27, 855, 10.1261/rna.078739.121 · DOI
  11. 2017, Type III CRISPR–Cas systems produce cyclic oligoadenylate second messengers, Nature, 548, 543, 10.1038/nature23467 · DOI · Paper page
  12. 2017, A cyclic oligonucleotide signaling pathway in type III CRISPR-Cas systems, Science, 357, 605, 10.1126/science.aao0100 · DOI · Paper page
  13. 2019, Cas13-induced cellular dormancy prevents the rise of CRISPR-resistant bacteriophage, Nature, 570, 241, 10.1038/s41586-019-1257-5 · DOI
  14. 2019, A type III CRISPR ancillary ribonuclease degrades its cyclic oligoadenylate activator, J. Mol. Biol., 431, 2894, 10.1016/j.jmb.2019.04.041 · DOI
  15. 2018, Ring nucleases deactivate type III CRISPR ribonucleases by degrading cyclic oligoadenylate, Nature, 562, 277, 10.1038/s41586-018-0557-5 · DOI
  16. 2019, CRISPR-Cas III-A Csm6 CARF domain is a ring nuclease triggering stepwise cA(4) cleavage with ApA > p formation terminating RNase activity, Mol. Cell, 75, 944, 10.1016/j.molcel.2019.06.014 · DOI
  17. 2020, Activation and self-inactivation mechanisms of the cyclic oligoadenylate-dependent CRISPR ribonuclease Csm6, Nat. Commun., 11, 1596, 10.1038/s41467-020-15334-5 · DOI
  18. 2020, Type III-A CRISPR-associated protein Csm6 degrades cyclic hexa-adenylate activator using both CARF and HEPN domains, Nucleic Acids Res., 48, 9204, 10.1093/nar/gkaa634 · DOI
  19. 2020, An anti-CRISPR viral ring nuclease subverts type III CRISPR immunity, Nature, 577, 572, 10.1038/s41586-019-1909-5 · DOI
  20. 2020, The dynamic interplay of host and viral enzymes in type III CRISPR-mediated cyclic nucleotide signalling, Elife, 9, e55852, 10.7554/eLife.55852 · DOI
  21. 2017, Structural basis for the bidirectional activity of bacillus nanoRNase NrnA, Sci. Rep., 7, 11085, 10.1038/s41598-017-09403-x · DOI
  22. 2018, Systematic prediction of genes functionally linked to CRISPR-Cas systems by gene neighborhood analysis, Proc. Natl Acad. Sci. U.S.A., 115, E5307, 10.1073/pnas.1803440115 · DOI · Paper page
  23. 2023, Antiviral type III CRISPR signalling via conjugation of ATP and SAM, Nature, 622, 826, 10.1038/s41586-023-06620-5 · DOI
  24. 2019, CRISPR-Cas: complex functional networks and multiple roles beyond adaptive immunity, J. Mol. Biol., 431, 3, 10.1016/j.jmb.2018.08.030 · DOI
  25. 2006, The NYN domains: novel predicted RNAses with a PIN domain-like fold, RNA Biol., 3, 18, 10.4161/rna.3.1.2548 · DOI
  26. 2017, Comprehensive classification of the PIN domain-like superfamily, Nucleic Acids Res., 45, 6995, 10.1093/nar/gkx494 · DOI
  27. 2017, Rae1/YacP, a new endoribonuclease involved in ribosome-dependent mRNA decay in Bacillus subtilis, EMBO J., 36, 1167, 10.15252/embj.201796540 · DOI
  28. 2018, Ribonuclease activity of MARF1 controls oocyte RNA homeostasis and genome integrity in mice, Proc. Natl Acad. Sci. U.S.A., 115, 11250, 10.1073/pnas.1809744115 · DOI · Paper page
  29. 2019, CRISPR-Cas in mobile genetic elements: counter-defence and beyond, Nat. Rev. Microbiol., 17, 513, 10.1038/s41579-019-0204-7 · DOI
  30. 2018, Human MARF1 is an endoribonuclease that interacts with the DCP1:2 decapping complex and degrades target mRNAs, Nucleic Acids Res., 46, 12008, 10.1093/nar/gky1011 · DOI · Paper page
  31. 2022, ColabFold: making protein folding accessible to all, Nat. Methods, 19, 679, 10.1038/s41592-022-01488-1 · DOI · Paper page
  32. 2023, DALI shines a light on remote homologs: one hundred discoveries, Protein Sci., 32, e4519, 10.1002/pro.4519 · DOI
  33. 2010, Binding and cleavage of CRISPR RNA by Cas6, RNA, 16, 2181, 10.1261/rna.2230110 · DOI
  34. 2011, Mature clustered, regularly interspaced, short palindromic repeats RNA (crRNA) length is measured by a ruler mechanism anchored at the precursor processing site, Proc. Natl Acad. Sci. U.S.A., 108, 21218, 10.1073/pnas.1112832108 · DOI · Paper page
  35. 2014, Genetic characterization of antiplasmid immunity through a type III-A CRISPR-Cas system, J. Bacteriol., 196, 310, 10.1128/JB.01130-13 · DOI
  36. 2014, Cas6 specificity and CRISPR RNA loading in a complex CRISPR-Cas system, Nucleic Acids Res., 42, 6532, 10.1093/nar/gku308 · DOI
  37. 2012, Structure and mechanism of the CMR complex for CRISPR-mediated antiviral immunity, Mol. Cell, 45, 303, 10.1016/j.molcel.2011.12.013 · DOI
  38. 2015, Crystal structure of the CRISPR-Cas RNA silencing Cmr complex bound to a target analog, Mol. Cell, 58, 418, 10.1016/j.molcel.2015.03.018 · DOI · Paper page
  39. 2017, Molecular determinants for CRISPR RNA maturation in the Cas10-Csm complex and roles for non-Cas nucleases, Nucleic Acids Res., 45, 2112, 10.1093/nar/gkw891 · DOI
  40. 2022, Critical roles for ‘housekeeping’ nucleases in type III CRISPR-Cas immunity, Elife, 11, e81897, 10.7554/eLife.81897 · DOI
  41. 2019, A type III-A CRISPR-Cas system employs degradosome nucleases to ensure robust immunity, Elife, 8, e45393, 10.7554/eLife.45393 · DOI
  42. 2009, RNA-guided RNA cleavage by a CRISPR RNA-Cas protein complex, Cell, 139, 945, 10.1016/j.cell.2009.07.040 · DOI · Paper page
  43. 2014, Programmable RNA shredding by the type III-A CRISPR-Cas system of Streptococcus thermophilus, Mol. Cell, 56, 506, 10.1016/j.molcel.2014.09.027 · DOI
  44. 2022, Diversity and dynamics of the CRISPR-Cas systems associated with Bacteroides fragilis in human population, BMC Genomics, 23, 573, 10.1101/2021.09.09.459629 · DOI
  45. 2021, Structural coordination between active sites of a CRISPR reverse transcriptase-integrase complex, Nat. Commun., 12, 2571, 10.1038/s41467-021-22900-y · DOI
  46. 2019, Investigation of the cyclic oligoadenylate signaling pathway of type III CRISPR systems, Methods Enzymol, 616, 191, 10.1016/bs.mie.2018.10.020 · DOI
  47. 2005, Method for assigning double-stranded RNA structures, Biotechniques, 38, 368, 370, 372, 10.2144/05383BM04 · DOI
  48. Lipkin, D., Talbert, P.T. and Cohn, M. (1954) The mechanism of the alkaline hydrolysis of ribonucleic acids. J. Am. Chem. Soc.76, 2871–287210.1021/ja01640a004 · DOI

Metadata

Authors
Chi, H., & White, M. F.
Affiliations
University of St Andrews (GB)
Corresponding author
White, Malcolm F.
ORCID
Venue
Biochemical Journal
Publisher
Portland Press Ltd.
Published
2024-06-17
Volume
481
Issue
12
Pages
793-804
ISSN
  • 0264-6021 (ISSN-L)
  • 1470-8728
DOI
10.1042/bcj20240151
PMC
PMC11346440
OpenAlex
W4398777861
Cited by
4
References
2
Citations by year
2026: 1 · 2025: 2 · 2024: 1
FWCI
0.54
Type
journal article
Language
en
Open access
Licence
Locations
  • Biochemical Journal (publishedVersion, cc-by)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • St Andrews Research Repository (St Andrews Research Repository) (submittedVersion, cc-by)
Funders
  • EC | European Research Council (101018608)
  • China Scholarship Council (202008420207)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › CRISPR and Genetic Engineering
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA regulation and disease
Keywords
Bacteroides fragilis, Cas10, antiviral defense
MeSH terms
Bacterial Proteins, Bacteroides fragilis, Models, Molecular, Ribonucleases, RNA Processing, Post-Transcriptional, RNA, Bacterial, CRISPR-Cas Systems, CRISPR-Associated Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review